New drug delays progression of glioma, a deadly brain cancer
Key takeawaysA targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer.In a study of 331 people with the disease, the drug was effective in lengthening the period of time before the patients ’ cancer worsened, and with no observed adverse effects.New treatment approaches for glioma are needed because current treatments, including chemotherapy and radiation, can cause neurological deficits.In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a...
Source: UCLA Newsroom: Health Sciences - June 4, 2023 Category: Universities & Medical Training Source Type: news
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
BRISBANE, Calif., June 04, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the“Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2023 Category: Drugs & Pharmacology Source Type: news
Chek-Mate for Gliomas
New research may make immunotherapy possible for hard-to-treat brain tumors. (Source: The Scientist)
Source: The Scientist - May 22, 2023 Category: Science Tags: News Source Type: news
Neuronal-glioma cross-talk | Science Signaling
Remodeling of neural circuits by glioma cells decreases patient survival. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - May 16, 2023 Category: Science Source Type: news
Imaging Biometrics partners with Prism Clinical Imaging
Imaging Biometrics and Prism Clinical Imaging have partnered to provide brai...Read more on AuntMinnie.comRelated Reading:
TeraRecon adds Imaging Biometrics' MRI image analysis to AI platform
Imaging Biometrics seeks FDA clearance for IB Zero G
Imaging Biometrics highlights findings on MRI-based glioma monitoring
Imaging Biometrics secures patent for zero-dose imaging software
Imaging Biometrics wins USC installation (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 20, 2023 Category: Radiology Source Type: news
Novartis Tafinlar + Mekinist Approved by FDA for Pediatric Patients with BRAF V600E Low-Grade Glioma
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS for standard of care1,2
Approval also... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 19, 2023 Category: Drugs & Pharmacology Source Type: news
Dabrafenib-Trametinib Combo Approved for Pediatric Gliomas Dabrafenib-Trametinib Combo Approved for Pediatric Gliomas
The targeted therapy combination beat chemotherapy on progression-free survival, but there was no difference in overall survival at the interim analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 17, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Targeted Combination Gets FDA Nod for Pediatric Glioma
(MedPage Today) -- The FDA announced on Thursday that it has approved the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib (Mekinist) for the treatment of pediatric patients 1 year and older with low-grade glioma... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 17, 2023 Category: American Health Source Type: news
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age. (Source: World Pharma News)
Source: World Pharma News - March 17, 2023 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
On March 16, 2023, the Food and Drug Administration approved dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formula (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
VTE risk low among COVID-19 outpatients
Despite high rates of venous thromboembolism (VTE) in hospitalized COVID-1...Read more on AuntMinnie.comRelated Reading:
Nomogram predicts venous thromboembolism in glioma patients
Disparities found in inferior vena cava filter placement, removal
Alternative method for diagnosing PE as effective as CTPA
CMS releases 2022 Medicare Physician Fee Schedule final rule
New PET/CT tracer effectively targets blood clots (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 14, 2023 Category: Radiology Source Type: news
Ultrasound ablation improves motor function in Parkinson's disease patients
Ultrasound ablation potentially improves motor function and reduces dyskinesi...Read more on AuntMinnie.comRelated Reading:
Ultrasound renal denervation helps reduce blood pressure
Contrast helps with echocardiography for aortic valve surgery
CEUS better than MRI for diagnosing liver, kidney tumors
Nomogram predicts venous thromboembolism in glioma patients
PET tracers predict prostate patient response to HIFU (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 1, 2023 Category: Radiology Source Type: news
Ultrasound renal denervation helps reduce blood pressure
Renal denervation via ultrasound can reduce daytime ambulatory systolic bloo...Read more on AuntMinnie.comRelated Reading:
Nomogram predicts venous thromboembolism in glioma patients
Researchers develop ultrasound 'tornado' technique to treat blood clots
POCUS achieves new heights in Mount Everest rescue
AI can guide POCUS exams by novice users in the COVID ICU
USPSTF advises against carotid artery stenosis screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 28, 2023 Category: Radiology Source Type: news
Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
Recent advances in cancer genomics have deepened the medical community ’s understanding of the molecular alterations in braintumours, more preciselysubclassifying patients into specific diagnoses.Understanding a patient ' sbraintumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes.The IDH1 R132H and ATRX antibodies are the latest additions to Roche ’s neuropathology portfolio, which contains 29 biomarkers.Basel, 23 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibo...
Source: Roche Media News - February 23, 2023 Category: Pharmaceuticals Source Type: news
